



**Beaker, Donna 6732117**

F, 54 yrs, 1/1/1970

*Beaker Testing Submitter*  
123 Smith Road  
Danville Pennsylvania 17821

**Authorizing Provider**

Test, Provider, MD C34270

F: C34270

Collected: 9/13/2024

**Surgical Pathology** (Final result)

S24-000165

Authorizing Provider:	Test, Provider, MD	Ordering Provider:	Test, Provider, MD
Ordering Location:	Laboratory, Danville	Collected:	09/13/2024
Pathologist:	Lab, Pathology Physician-One	Received:	09/18/2024 0937

**Final Diagnosis**

**A. Endocervix, ECC, curetting:**

High grade squamous intraepithelial lesion (CIN3, severe dysplasia).

**B. Cervix, Cervical biopsy at 5 o'clock, biopsy:**

Benign cervical mucosa with atrophy.

**C. Cervix, Cervical biopsy at 11 o'clock, biopsy:**

Benign cervical mucosa with atrophy.

**D. Cervix, Cervical biopsy at 1 o'clock, biopsy:**

Benign cervical mucosa with atrophy.

Electronically signed by Lab, Pathology Physician-One on 9/18/2024 at 0945

**Clinical History**

HGSIL Pap

**Gross Description**

A. Endocervix.

Received in formalin with a container labeled with "Donna Beaker", "1/1/1970", and "ECC". Received is a 0.5 x 0.5 x 0.1 cm aggregate of mucoid material. The specimen is submitted entirely in cassette A1. Gross By: SF

B. Cervix.

Received in formalin with a container labeled with "Donna Beaker", "1/1/1970", and "Cervix at 5 o'clock". Received is one fragment of tan-white tissue measuring 0.6 cm in greatest dimension. The specimen is placed in a biopsy bag

and entirely submitted in cassette B1. Gross By: SF

## C. Cervix.


Received in formalin with a container labeled with "Donna Beaker", "1/1/1970", and "Cervix at 11 o'clock". Received is one fragment of tan-white tissue measuring 0.5 cm in greatest dimension. The specimen is placed in a biopsy bag and entirely submitted in cassette C1. Gross By: SF

## D. Cervix.

Received in formalin with a container labeled with "Donna Beaker", "1/1/1970", and "Cervix at 1 o'clock". Received is one fragment of tan-white tissue measuring 0.3 cm in greatest dimension. The specimen is placed in a biopsy bag and entirely submitted in cassette D1. Gross By: SF

## Microscopic Description

A. Section of the endocervical curetting contains portions of endocervical glandular epithelium and mucous. There are detached fragments of dysplastic epithelium suggesting a high grade squamous intraepithelial lesion (CIN 3, severe dysplasia). There are also focal changes suggesting HPV associated cellular change. Immunocytochemical assays were performed. In the areas of high grade squamous intra epithelial lesion (HSIL) there is strong p16 positivity and numerous nuclei throughout the thickness of the epithelium HSIL in endocervical curetting are decorated with MiB-1. These findings support the morphologic impression of a HSIL.



B. Sections and levels of the cervical biopsy at 5 o' clock contain fragments of cervix from the cervical/endocervical junction. There is significant atrophic change in the epithelium. There is no evidence of HPV associated cellular change or of frank dysplasia. Immunocytochemical assays were performed. The atrophic epithelium is essentially negative for p16 without any nuclear labeling with MiB-1. These findings support the morphologic impression of atrophy.

C. Sections and levels of the cervical biopsy at 11 o' clock contain fragments of cervix. The epithelium is squamous with significant atrophy. There is no evidence of HPV associated cellular change or of frank dysplasia.

D. Sections and levels of the cervical biopsy at 1 o' clock contain fragments of cervix. The epithelium is squamous. There is no evidence of HPV associated cellular change or of frank dysplasia.

## Sign Out Location

Pathologist sign out performed at Geisinger Medical Center (GMC), 100 N Academy Ave, Danville, PA 17822. 1-800-695-6491

# Geisinger

*they are not intended to replace a complete review of the final diagnostic report.*

*The following statement applies to Flow Cytometry, Histology, In situ Hybridization Assays and Molecular Genetics. This test was developed and performed at Geisinger Medical Center and its performance characteristics determined by Geisinger Medical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Special stains, including histochemical stains, and studies using immunologic and ISH methodology (where applicable) are performed with appropriate positive and negative control reactions.*

## Resulting Labs

---

LABORATORY GMC, 100 N Academy Ave, Danville PA  
17822  
Director: Myra Wilkerson, MD

800-695-6491